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Background. Integrated positron emission tomography/computed tomography (PET-CT) is a well-validated modality for assessing 
mediastinal lymph node metastasis in non-small-cell lung cancer (NSCLC), which determines management and predicts survival. 
Tuberculosis (TB) is known to lead to false-positive PET-CT findings.
Objectives. To assess the diagnostic accuracy of PET-CT in identifying mediastinal lymph node involvement of NSCLC in a high 
TB-endemic area.
Methods. Patients who underwent both PET-CT and lymph node tissue sampling for the investigation of suspected NSCLC were 
prospectively included in this observational study. Results were analysed per patient and per lymph node stage. A post-hoc analysis was 
performed to test the validity of a maximum standardised uptake value (SUV max) cut-off for lymph node positivity.
Results. PET-CT had a sensitivity of 92.6%, specificity of 48.6%, positive predictive value of 56.8% and negative predictive value (NPV) of 
90.0% in the per-patient analysis. Diagnostic accuracy was 67.2%. Similar values were obtained in the per-lymph node stage analysis. TB 
was responsible for 21.1% of false-positive results. A SUVmax cut-off of 4.5 yielded an improvement in diagnostic accuracy from 64.0% to 
84.7% compared with a cut-off of 2.5, but at the cost of decreasing the NPV from 90.6% to 83.5%.
Conclusion. In a high TB-endemic area, PET-CT remains a valuable method for excluding mediastinal lymph node involvement in NSCLC. 
Patients with a negative PET-CT may proceed to definitive management without further invasive procedures. However, PET-CT-positive 
lymph nodes require pathological confirmation, and the possibility of TB must be considered.
S Afr Med J 2015;105(2):145-150. DOI:10.7196/SAMJ.8357
145       February 2015, Vol. 105, No. 2
Lung cancer is the most common cause of death 
from cancer worldwide, with equally poor survival in 
developed and developing regions.[1] Non-small-cell 
lung cancer (NSCLC) comprises 75 - 80% of lung 
cancer cases.[2] Determining mediastinal lymph node 
involvement is fundamental in the staging of NSCLC and has been 
shown to have prognostic significance.[3] The node (N) stage determines 
the treatment strategy, as patients with N2 lymph node metastasis are 
considered inoperable and only selected patients with this stage are 
eligible for chemotherapy and/or radiotherapy with curative intent.[4,5]
At present, integrated positron emission tomography/computed 
tomography (PET-CT) is recognised as being superior to PET alone, 
CT alone, or visual comparison of PET and CT images for the 
assessment of mediastinal lymph node involvement in NSCLC,[6] 
with an average sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) of 73%, 80%, 78% and 
91%, respectively.[2] This imaging modality has been available in the 
Western world since the 1990s, forming an integral part of mediastinal 
lymph node staging in those regions,[7] but has only recently become 
standard practice in South Africa (SA). It has been suggested that 
negative PET-CT for mediastinal lymph node involvement requires 
no further invasive staging and surgical resection may proceed.[8]
Developing regions, particularly high tuberculosis (TB)-endemic 
areas, face the potential challenge of interpreting PET-CT images 
as false positive in TB-involved lymph nodes.[2,5,9,10] The effect of TB 
on PET-CT staging of NSCLC has previously been investigated in 
areas with an incidence of TB of approximately 73/100 000 popula-
tion.[5,11,12] Two studies from Korea showed that the sensitivity (75% 
and 46%, respectively) and PPV (27% and 72%) of PET-CT were 
adversely affected, but that a high specificity (85% and 98%) and NPV 
(98% in both studies) were maintained, especially when calcification 
and attenuation of nodes on CT was taken into account.[5,11] Recent 
data from China demonstrated a similar pattern of results, with a 
relatively low sensitivity (61.8% and 78.6% for adenocarcinoma and 
squamous cell carcinoma, respectively) and specificity (66.3% and 
45.5%), and a high NPV (80.9% and 87%). The authors stated that 
the high incidence of granulomatous disease in their region impacted 
significantly on the rate of false-positive results in their study.[12] 
According to the World Health Organization, the incidence of TB in 
SA is 1 000/100 000 population.[13] To date, no study of the efficacy 
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of this modality for mediastinal lymph node 
staging in NSCLC in an area with such a high 
incidence of TB has been conducted.
The aim of this study was to assess the 
diagnostic accuracy of integrated PET-CT in 
detecting NSCLC metastases in mediastinal 
lymph nodes in patients from a high 
TB-endemic area.
Methods
Study design and patient population
Tygerberg Academic Hospital (TAH), 
Cape Town, provides tertiary services for 
approximately 2 million people in the Western 
Cape Province of SA, draining the eastern 
subdistrict of the Cape Town metropole and 
surrounding areas. All patients referred with 
a suspicion of NSCLC to the Division of 
Pulmonology at TAH from January 2009 to 
December 2013 were eligible for inclusion in 
this observational study. Ethical approval for 
the study was granted by the Health Research 
Ethics Committee of Stellenbosch University.
Patients with an intermediate to high pre-
test probability of malignancy according 
to clinical guidelines[14] were referred for 
PET-CT according to the standardised 
diagnostic algorithm that was used at the 
time of the study, with the PET-CT generally 
performed before tissue sampling (Fig. 1). 
Patients who had no lymph node tissue 
sampling performed were excluded. Patients 
were followed up to the point of referral for 
definitive treatment or palliation.
PET-CT scanning
All studies were performed from the 
base of skull to the upper thigh with a 
Siemens Biograph or Philips Gemini PET-
CT system with 16-slice uncontrasted CT 
(Fig. 2). The procedure was performed 
according to European Association of 
Nuclear Medicine guide lines.[15] Patients 
fasted for at least 6 hours prior to the study. 
Blood glucose levels were tested prior to the 
scan, which was postponed if the patient 
had a level of >11.1 mmol/L. Patients lay 
supine for 30 minutes prior to the study, and 
for a further 60 minutes, without talking, 
after injection of 18fluorodeoxyglucose 
(FDG). An FDG dose of 7 - 13 mCi was 
administered according to body weight. All 
images were interpreted by an experienced 
nuclear medicine physician and at least 
one radiologist, and independently by a 
respiratory physician. Lymph node positivity 
was defined as any increase in FDG uptake 
compared with the mediastinal blood 
pool. Nodes were considered negative if 
they demonstrated a lower or equal FDG 
uptake compared with the mediastinal blood 
pool. The intensity of the FDG uptake in 
lymph nodes of interest was quantified 
using a Philips EBW workstation. A cursor 
was manually placed at the site of highest 
visual uptake within the lymph node, and 
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Fig. 1. Algorithm utilised during the study period for the evaluation of patients with suspected lung cancer. (CXR = chest radiograph; neg. = negative; pos. = positive; 
M = distant metastases; mediast. LNs = mediastinal lymph nodes; PT = primary tumour; FB = flexible bronchoscopy; EBUS = endobronchial ultrasound; EUS = 
endoscopic ultrasound; TTNA = transthoracic needle aspiration; N = lymph node metastases; T = tumour stage.)
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the maximum standardised uptake value 
(SUVmax) was obtained from this slice using 
a circular region of interest with an 8 mm 
diameter. Lymph nodes were identified by 
accepted nomenclature according to the 
International Association for the Study of 
Lung Cancer lymph node map.[4] These were 
further grouped into N1, N2 and N3 zones 
for prognostic purposes.[4]
Tissue sampling
Cells were obtained from lymph nodes of 
interest by an experienced interventional 
pulmonologist via endoscopic transbronchial 
needle aspiration, or fine-needle aspiration 
where accessible. Cytologically positive 
samples were considered to be evidence 
for the presence of metastatic malignancy, 
but negative samples were not considered 
sufficient evidence for the absence of 
malignancy.
Where further sampling was required, 
biopsy of suspicious lymph nodes was 
performed by mediastinoscopy. Alternatively, 
the entire lesion with surrounding lymph 
nodes was resected in an attempt at cure. All 
histological specimens thus obtained were 
considered definitive for both lymph node 
positivity and negativity. Biopsy specimens 
were concurrently tested for TB via staining 
for acid-fast bacilli.
Bronchial lavage and/or sputum samples 
were obtained from each patient and tested 
for TB via Ziehl-Neelsen staining (this 
being replaced by GeneXpert in 2013) and 
mycobacterial culture. These samples were 
also sent for routine microscopy, culture and 
sensitivity.
Statistical aspects
Descriptive statistics were performed. 
Analyses were conducted of data collected 
per patient, as well as per lymph node stage 
sampled (N1, N2, N3). The sensitivity, 
specificity, PPV, NPV, likelihood ratios (LRs) 
and diagnostic accuracy of PET-CT were 
calculated using standard methods.
A post-hoc secondary analysis of the 
SUVmax of all individual lymph nodes 
sampled was undertaken with the aim 
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clinical probability of lung cancer (N=224) 
LN sampled Excluded (n=160)
72 metastatic disease
52 alternative diagnosis
16 loss to follow up
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64 patients
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(false pos.)
Tissue pos.
(false neg.)
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(true neg.)
25 patients
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19 patients
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2 patients
3 LN stages
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Fig. 3. Consort diagram. Alternative diagnoses included 21 patients with pulmonary infection of which 16 were tuberculosis, 28 patients with post-infectious 
changes with no organism identified, and 3 patients with non-carcinomatous tumours. (LN = lymph node; neg. = negative; pos. = positive.)
Fig. 2. (a) PET-CT scan demonstrating a left 
hilar lymph node with positivity due to proven 
tuberculosis. (b) PET-CT scan demonstrating 
a subcarinal lymph node with positivity due to 
metastatic non-small-cell lung cancer.
A
B
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of identifying the SUVmax cut-off for 
designation of lymph nodes as ‘positive’ or 
‘negative’ that would prove most clinically 
relevant. A receiver operating characteristic 
(ROC) curve was used to identify the SUVmax 
cut-off with the highest diagnostic accuracy. 
The SUVmax cut-off of 2.5 has been used in 
previous studies as a comparison value. It 
was therefore subsequently compared with 
the value identified by the ROC curve with 
regard to sensitivity, specificity, PPV, NPV 
and diagnostic accuracy.[16]
Results
Study population
During the study period, a total of 224 
patients were referred for PET-CT based on 
an intermediate or high pre-test probability 
of lung cancer (Fig. 3). A total of 64 patients 
underwent extensive lymph node sampling 
and were therefore included in the study, with 
111 separate lymph node stages sampled. 
Demographic data are depicted in Table 1.
PET-CT findings
In the per-patient analysis, PET-CT was 
found to have a sensitivity of 92.6%, 
specificity of 48.6%, PPV of 56.8%, NPV of 
90.0%, positive LR of 1.8 and negative LR of 
0.15 (Table 2). The diagnostic accuracy was 
67.2%. Of the false positives, 21.1% were 
attributed to active TB infection and 78.9% 
were reactive lymph nodes. In the per-
lymph node stage analysis, the sensitivity 
was 93.2%, specificity 50.0%, PPV 55.4% 
and NPV 91.7%, with a positive LR of 
1.9, and negative LR of 0.14. Diagnostic 
accuracy was 67.6%.
In the secondary analysis of SUVmaxes of 
individual nodes, the ROC curve identified 
a SUVmax cut-off of 4.5 as offering the 
highest overall diagnostic accuracy (Fig. 4). 
The comparison SUVmax cut-off of 2.5 was 
analysed and found to have a sensitivity of 
95.7%, specificity of 36.3%, PPV of 56.8% 
and NPV of 90.6% when applied to these 
data. The diagnostic accuracy was 64.0%. A 
SUVmax cut-off of 4.5 yielded a sensitivity 
of 80.0%, specificity of 88.8%, PPV of 86.2% 
and NPV of 83.5% (Table 3). The diagnostic 
accuracy was 84.7%.
Discussion
In this first study of PET-CT for evaluation 
of mediastinal lymph node staging in NSCLC 
in SA, we have demonstrated that PET-CT 
had a high sensitivity of 92.6% and 93.2% per 
patient and per lymph node stage, respectively, 
and a high NPV of 90% and 91.7%. It had 
a low specificity of 48.6% and 50.0% and a 
low PPV of 56.8% and 55.4%. Moreover, we 
found favourable negative LRs. The diagnostic 
accuracy was 67.2% and 67.6%, respectively. 
More than 20% of false-positive PET-CT scan 
results were attributable to active TB, once 
again highlighting that TB can mimic lung 
cancer in the clinical setting.
These results confirm the value of PET-
CT for excluding lymph node involvement 
in NSCLC in a high TB-endemic area. The 
role of PET-CT can therefore be considered 
the same as in non-TB-endemic areas, 
where it is used to direct node biopsy 
rather than to aid in diagnosis. A patient 
with a PET-CT that is negative for any 
lymph node involvement may be considered 
to be accurately staged and therefore 
proceed to definitive management of the 
cancer without further invasive staging 
investigations. Importantly, in the SA 
context a positive lymph node on PET-
CT has an approximately 50% chance of 
Table 1. Demographic data: characteristics of the population screened during the 
study period, with patients included in the study compared with patients excluded
Study population Patients excluded
Males, n (%) 39 (60.9) 96 (60.0)
Females, n (%) 25 (39.1) 64 (40.0)
Age range (years), n (%)
<40 2 (3.1) 5 (3.1)
40 - 50 11 (17.2) 17 (10.6)
51 - 60 21 (32.8) 52 (32.5)
61 - 70 20 (31.3) 49 (30.6)
71 - 80 10 (15.6) 32 (20.0)
>80 0 (0.0) 5 (3.1)
Mean age (years) (standard deviation) 59.3 (10.2) 61.6 (10.7)
Histological type*, n (%)
Adenocarcinoma 34 (59.7) 49 (45.4)
Squamous cell carcinoma 16 (28.1) 38 (35.2)
Undifferentiated large-cell carcinoma 4 (7.0) 17 (15.7)
Other 3 (5.3) 1 (0.9) 
Clinical stage*, n (%)
Stage I 10 (17.5) 3 (2.9)
Stage II 18 (31.6) 4 (3.8)
Stage III 22 (38.6) 41 (39.0)
Stage IV 7 (12.3) 57 (54.3)
*In patients with proven NSCLC.
Table 2. PET-CT results: data acquired from the comparison of PET-CT findings 
and tissue sampling, grouped per patient and per lymph node stage, and statistical 
analysis thereof
Per-patient analysis Per-lymph node stage analysis
True positive, n (%) 25 (39.1) 41 (36.9)
True negative, n (%) 18 (28.1) 34 (30.6)
False positive, n (%) 19 (29.7) 33 (29.7)
False negative, n (%) 2 (3.1) 3 (2.7)
Sensitivity (95% CI) 92.6 (0.743 - 0.987) 93.2 (0.803 - 0.982)
Specificity (95% CI) 48.6 (0.322 - 0.653) 50.0 (0.376 - 0.624)
PPV (95% CI) 56.8 (0.411 - 0.713) 55.4 (0.434 - 0.668)
NPV (95% CI) 90.0 (0.669 - 0.983) 91.7 (0.764 - 0.978)
Positive likelihood ratio (95% CI) 1.803 (1.295 - 2.511) 1.864 (1.445 - 2.403)
Negative likelihood ratio (95% CI) 0.152 (0.038 - 0.611) 0.136 (0.044 - 0.419)
CI = confidence interval.
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being a false positive. All such patients 
therefore require further investigations 
for pathological confirmation before they 
can be accurately staged and appropriately 
managed. Initial studies involving this 
modality in other regions of the world found 
a pooled average sensitivity, specificity, 
PPV and NPV of 73%, 80%, 78% and 
91%, respectively.[2] The present study in 
a high TB-endemic region demonstrated 
the anticipated reduction in specificity and 
PPV, which is attributable to the high rate of 
false-positive TB-infected or reactive nodes. 
However, our sensitivity and NPV are equal 
or superior to these international values. We 
postulate that the higher rate of pick-up of 
true-negative nodes in our study may be due 
to our method of combined analysis of PET-
CT images by a nuclear medicine physician 
and a radiologist, who take into account 
their own judgement of the appearance of 
the lymph nodes and attenuation of the 
nodes on CT, as well as interpreting the PET. 
Studies have demonstrated that lymph nodes 
with higher attenuation (>70 Hounsfield 
units) or calcification on CT have a much 
higher probability of being benign. Using 
these additional criteria for interpretation 
of images on PET-CT improves diagnostic 
accuracy, even in a TB-endemic area.[5,11,12]
Previous studies conducted in high 
TB-endemic areas did not demonstrate the 
anticipated reduction in specificity. In fact, 
these studies found a reduction in sensi-
tivity.[5,11,12] These authors proposed that 
this may have been due to the selective 
inclusion of patients of lower clinical stage 
with possible micrometastases to lymph 
nodes that did not demonstrate positivity 
on PET-CT, as well as the designation of all 
calcified lymph nodes as benign. It is worth 
considering that the present study was 
inadvertently subject to the same selective 
inclusion, although not to the same 
degree, and did not suffer corresponding 
losses in sensitivity. The present study 
does, however, agree with the previous 
studies[5,11,12] in the reduction of PPV, with 
preservation of NPV.
An ROC curve has been utilised in previous 
studies to identify the SUVmax cut-off with the 
highest diagnostic accuracy for the prediction 
of malignancy in mediastinal lymph nodes 
on PET-CT. Values identified in these studies 
included 4.4 and 5.3, yielding a diagnostic 
accuracy of 92% and 98%, respectively.[16,17] 
Although our post-hoc analysis of proposed 
SUVmax cut-offs suggested that a cut-off of 
4.5 conferred an improvement in diagnostic 
accuracy from 64.0% to 84.7% compared 
with a cut-off of 2.5, it came at the cost 
of decreasing the sensitivity from 95.7% to 
80.0% and the NPV from 90.6% to 83.5%. As 
PET-CT is used to exclude mediastinal spread 
rather than diagnose it, the reduction in NPV 
renders the cut-off of 4.5 less appropriate for 
clinical use.
The strength of the present study lies 
in the substantial number of lymph nodes 
sampled, and the prospective method in 
which the data were collected. A potential 
limitation was the necessary exclusion of a 
large number of patients – especially those 
in higher clinical stages of disease – prior 
to lymph node sampling. However, this was 
unavoidable as the study was conducted 
within the parameters of a normal clinical 
setting, and all decisions regarding invasive 
investigations were made in the interests of 
providing best patient care.
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Fig. 4. ROC curve of SUVmaxes of individual lymph nodes. The value 4.495 is identified as having the 
highest overall diagnostic accuracy.
Table 3. Proposed SUVmax cut-off value results: data acquired from grouping 
individually sampled lymph nodes as positive or negative according to proposed 
SUVmax cut-off values of 2.5 and 4.5 (identified by ROC curve in the present study), 
and statistical analysis thereof
SUVmax cut-off 2.5 SUVmax cut-off 4.5
True positive, n (%) 67 (44.7) 56 (37.3)
True negative, n (%) 29 (19.3) 71 (47.3)
False positive, n (%) 51 (34.0) 9 (6.0)
False negative, n (%) 3 (2.0) 14 (9.3)
Sensitivity (95% CI) 95.7 (0.872 - 0.989) 80.0 (0.684 - 0.883)
Specificity (95% CI) 36.3 (0.260 - 0.478) 88.8 (0.792 - 0.944)
PPV (95% CI) 56.8 (0.474 - 0.658) 86.2 (0.748 - 0.931)
NPV (95% CI) 90.6 (0.738 - 0.976) 83.5 (0.736 - 0.904)
Positive likelihood ratio (95% CI) 1.501 (1.264 - 1.784) 7.111 (3.801 - 13.306)
Negative likelihood ratio (95% CI) 0.118 (0.037 - 0.373) 0.225 (0.141 - 0.361)
CI = confidence interval.
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Conclusion
PET-CT remains a valuable method for excluding mediastinal lymph 
node metastases in the staging of NSCLC in a high TB-endemic area, 
because of its high sensitivity and NPV. A patient with negative PET-
CT for mediastinal lymph node involvement may therefore safely and 
swiftly proceed to curative surgical intervention without undergoing 
further invasive staging procedures. However, the low specificity 
and PPV indicate that the finding of a positive lymph node on this 
imaging modality requires pathological confirmation, and that the 
possibility of TB must be considered.
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